Glenmark Pharmaceuticals Ltd shares secure VAI classification from U.S. FDA for Goa facility
Why did Glenmark Pharmaceuticals Ltd shares jump today?
Glenmark Pharmaceuticals Ltd shares saw a modest increase of 0.38% today, trading at ₹2472.3 as of 11:14 AM on Wednesday. The stock's upward movement is directly linked to a positive regulatory update the company released regarding its operations in India.
On September 23, 2026, Glenmark Pharmaceuticals announced in a filing with the stock exchanges that it had received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa. This report is a standard follow-up to an FDA inspection and confirms the conclusion of the agency's review of the plant.
Crucially, the facility was assigned a "Voluntary Action Indicated" (VAI) classification. This is a favorable outcome for pharmaceutical companies, as it means that while some minor objectionable conditions were found, the FDA does not require any major corrective actions and considers the matter resolved. Receiving a clean EIR with a VAI status removes uncertainty and is a significant positive for investor confidence, as it ensures the uninterrupted supply of medicines from this key manufacturing site to the U.S. market, which is a major revenue contributor.
What does Glenmark Pharmaceuticals Ltd do?
Glenmark Pharmaceuticals Ltd is a research-led, global pharmaceutical company. The company is involved in the pharmaceutical sector, with a focus on research and manufacturing.
Its operations include a formulations manufacturing facility located in Goa, India. This facility has undergone an inspection by the U.S. Food and Drug Administration (FDA) and has been classified with a Voluntary Action Indicated (VAI) status.
Glenmark Pharmaceuticals Ltd Financials
In CroresBased on the provided data, Glenmark Pharmaceuticals Ltd reported revenue of ₹3760.28 crores for the quarter ended March 2026, which increased to ₹3931.73 crores by June 2026. Correspondingly, the company's profit after tax showed a notable rise, moving from ₹301.41 crores in the March quarter to ₹482.92 crores in the subsequent June quarter. This represents a positive financial trend, with revenue experiencing steady growth and profit surging significantly quarter-over-quarter, indicating improved operational performance and profitability.
Glenmark Pharmaceuticals Ltd Shareholding Pattern
Promoter holding stands at 46.65% of the total share capital. Foreign Institutional Investors (FIIs) hold 20.89% stake in the company, while Domestic Institutional Investors (DIIs) hold 18.6%. Public shareholders hold the remaining 13.85% stake in Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd FAQs
Q: Why did Glenmark shares jump 0.38% today?
Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?
As per the latest data, promoters hold 46.65% stake in Glenmark Pharmaceuticals Ltd, while FII holding stands at 20.89%. Domestic institutional investors hold 18.6%, and public shareholders account for 13.85% of the equity.
Q: What is the current stock price of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd shares are currently trading at ₹2472.3, recording a gain of 0.38% from the previous close.
Q: What is the market capitalization of Glenmark Pharmaceuticals Ltd?
The company currently has a market capitalization of ₹69774.41 crore, reflecting its valuation in the Indian equity market.